Janux Therapeutics (JANX) has shared encouraging interim results from its Phase 1 clinical trial of JANX007, a PSMA-targeted investigational therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). These findings indicate that JANX007 achieves sustainable patient responses while maintaining a manageable safety profile that competes well with other approved and experimental treatments for mCRPC.
The company plans to discuss these results further during a virtual event on Monday, December 1, 2025, at 4:30 PM ET. A highlighted advantage of the study was the potential for transitioning patients to bi-weekly dosing, which may offer significant convenience benefits. Janux is optimistic about exploring JANX007's effectiveness in earlier-stage mCRPC, where it could offer improved tolerability and durability of treatment outcomes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.